肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：过继细胞治疗恶性胶质瘤过程中T细胞与造血干细胞之间的影响

2018-08-29 MedSci MedSci原创

过继细胞治疗T细胞造血干细胞
关注

过继T细胞免疫治疗正逐渐成为治疗外周及中枢神经系统肿瘤的治疗策略。在外周肿瘤中，过继细胞治疗的有效性依赖肿瘤微环境中的DC细胞。但是中枢神经系统中缺乏DC细胞作为抗原呈递细胞。CLIN CANCER RES近期发表了一篇文章，研究过继回输肿瘤活化的T细胞和骨髓来源的造血干/祖细胞（HSPCs）是否可以使中枢神经系统出现瘤内DC增殖。

过继T细胞免疫治疗正逐渐成为治疗外周及中枢神经系统肿瘤的治疗策略。在外周肿瘤中，过继细胞治疗的有效性依赖肿瘤微环境中的DC细胞。但是中枢神经系统中缺乏DC细胞作为抗原呈递细胞。CLIN CANCER RES近期发表了一篇文章，研究过继回输肿瘤活化的T细胞和骨髓来源的造血干/祖细胞（HSPCs）是否可以使中枢神经系统出现瘤内DC增殖。

作者在体内实验中研究过继细胞治疗过程中HSPC分化情况，在体外实验中研究HSPC增殖和分化。使用FACS，ELISAs研究HSPC来源的细胞亚型及功能。通过存活实验研究HSPC分化和功能对抗肿瘤效果的影响。研究结果表明，联合过继细胞治疗回输HSPC导致活化的CD86+CD11c+MHCⅡ+细胞产生，这种细胞与脑肿瘤微环境中的DC亚型和功能一致。这种瘤内的DC细胞可以大量取代宿主的髓源性抑制细胞。在过继细胞治疗过程中，胶质瘤中HSPC来源的细胞需要T细胞分泌的IFNγ分化为DC细胞，活化T细胞从而抑制颅内肿瘤。

文章最后认为，HSPCs可以作为一种细胞治疗方案。DC疫苗可以在外周肿瘤中诱导免疫反应，输入HSPC可以特异性的诱导瘤内DC生成，增强T细胞反应从而抑制胶质瘤。

原始出处：
Tyler J Wildes,Adam Grippin,et al.Cross-talk between T cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.CLIN CANCER RES.August 2018 doi:10.1158/1078-0432.CCR-17-3061

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2018112, encodeId=a210201811276, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#过继细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94121, encryptionId=974294121a5, topicName=过继细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Sep 26 00:30:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271466, encodeId=60ee12e146691, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494641, encodeId=ac5814946417b, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341755, encodeId=4819341e551a, content=希望可以看到临床数据, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Thu Aug 30 09:07:10 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341736, encodeId=6871341e36a4, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:07:17 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-09-26 apoenzyme

    #过继细胞治疗#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2018112, encodeId=a210201811276, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#过继细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94121, encryptionId=974294121a5, topicName=过继细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Sep 26 00:30:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271466, encodeId=60ee12e146691, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494641, encodeId=ac5814946417b, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341755, encodeId=4819341e551a, content=希望可以看到临床数据, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Thu Aug 30 09:07:10 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341736, encodeId=6871341e36a4, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:07:17 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-31 huanbaofeng

    #造血干细胞#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2018112, encodeId=a210201811276, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#过继细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94121, encryptionId=974294121a5, topicName=过继细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Sep 26 00:30:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271466, encodeId=60ee12e146691, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494641, encodeId=ac5814946417b, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341755, encodeId=4819341e551a, content=希望可以看到临床数据, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Thu Aug 30 09:07:10 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341736, encodeId=6871341e36a4, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:07:17 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-31 俅侠

    #造血#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2018112, encodeId=a210201811276, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#过继细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94121, encryptionId=974294121a5, topicName=过继细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Sep 26 00:30:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271466, encodeId=60ee12e146691, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494641, encodeId=ac5814946417b, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341755, encodeId=4819341e551a, content=希望可以看到临床数据, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Thu Aug 30 09:07:10 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341736, encodeId=6871341e36a4, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:07:17 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 asuraxia

    希望可以看到临床数据

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2018112, encodeId=a210201811276, content=<a href='/topic/show?id=974294121a5' target=_blank style='color:#2F92EE;'>#过继细胞治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94121, encryptionId=974294121a5, topicName=过继细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Sep 26 00:30:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271466, encodeId=60ee12e146691, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95001, encryptionId=a0ff950018f, topicName=造血干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494641, encodeId=ac5814946417b, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Fri Aug 31 12:30:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341755, encodeId=4819341e551a, content=希望可以看到临床数据, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Thu Aug 30 09:07:10 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341736, encodeId=6871341e36a4, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:07:17 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 kafei

    学习了谢谢

    0

相关资讯

Science：癌症新疗法——以子之矛，攻子之盾

5月9日Science杂志上公布的一项成果，报道了一位43岁女性癌症患者绝处逢生的故事，这位患者患有晚期癌症，尽管进行了化疗治疗，但其癌细胞还是从她的胆管扩散到肝脏和肺部区域。 来自美国国家癌症研究所的研究人员对这位患者的基因组进行了测序，从她的免疫系统中找到了那些能攻击癌细胞中一个特殊突变的细胞，然后在实验室中培养这些免疫细胞，并将培养后的上亿个细胞注入回患者血液中

CLIN CANCER RES：靶向肿瘤脉管系统增强免疫检查点抑制剂联合过继细胞治疗疗效

异常的血流及内皮细胞无反应性在许多实体肿瘤中存在，阻滞了细胞毒T淋巴细胞肿瘤（CTL）浸润。这也导致了使用抗体单药（如免疫检查点抑制剂）直接靶向T细胞调节通路的免疫治疗耐药。CLIN CANCER RES近期发表了一篇文章，研究NGR-TNF，一种靶向肿瘤血管的TNF衍生物，是否可以增加CTL瘤内浸润以及是否可以使肿瘤对PD-1和CTLA-4受体抗体敏感。